RT Crémieux：当前最令人兴奋的长寿趋势是我们正在真正战胜痴呆症
当前最令人兴奋的长寿趋势是我们正在真正战胜痴呆症。与几十年前相比，70、75、80岁等特定年龄段的痴呆症患病率正在下降。如今90岁老人患痴呆症的风险比1984年时降低了一半以上！
相关报道
The article examines the field of longevity research, focusing on Altos Labs and cellular rejuvenation. While acknowledging widespread hype around anti-aging breakthroughs, it details serious scientific work on biological reprogramming that could fundamentally extend human healthspan, distinguishing genuine advances from exaggerated claims.
The article examines the growing field of cellular rejuvenation research, particularly work at Altos Labs, which aims to reverse biological aging at the cellular level. While acknowledging that much longevity science is overhyped, it highlights that this line of research could fundamentally reshape medicine and human healthspan if it succeeds.
Researchers have discovered unexpected cancer-like mutations in the brain's immune cells that may contribute to Alzheimer's disease progression. These mutations occur in microglia cells and appear to drive inflammation and neurodegeneration. The findings suggest new potential therapeutic targets for Alzheimer's treatment.
The article explores the growing interest among wealthy and powerful individuals in longevity and life-extension technologies, examining the ethical and societal implications if such breakthroughs become accessible only to a select few.
The largest randomized controlled trial of rapamycin, a leading longevity drug, is currently underway. This human trial aims to provide evidence about the drug's potential effects on aging and lifespan.